EIR BIOPHARMA, INC.

92 Natoma Street, Suite 200

San Francisco, California 94105

 

Date: November 16, 2026

 

 VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

 

Re: EIR BIOPHARMA, INC.
  Request for Withdrawal of Registration Statement on Form S-1 (File No. 333-293522)

 

Ladies and Gentlemen:

 

On February 17, 2026, EIR Biopharma, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “Commission”) the above referenced registration statement on Form S-1 (including all exhibits thereto) (the “Registration Statement”).

 

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement, effective as of the date hereof or at the earliest practicable date hereafter. The Company is requesting withdrawal because it does not intend to proceed with the public offerings contemplated by the Registration Statement at this time. The Registration Statement has not been declared effective by the Commission, and no securities have been issued or sold under the Registration Statement. Therefore, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by Rule 477(a) under the Securities Act.

 

The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, in accordance with Rule 457(p) under the Securities Act, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use by the Company.

 

Please direct any questions or comments regarding this matter to the Company’s counsel, Bevilacqua PLLC, attention: Louis Bevilacqua, Esq., at (202) 869-0888 ext. 100.

 

Thank you for your assistance in this matter.

 

Very truly yours,  
   
EIR BIOPHARMA, INC.  
     
By: /s/ Martin Schroeder  
Name: Martin Schroeder  
Title: Chairman and Chief Executive Officer  

 

cc: Bevilacqua PLLC